Dexcom, Inc. Files 8-K with Financial Updates

Ticker: DXCM · Form: 8-K · Filed: 2025-02-13T00:00:00.000Z

Sentiment: neutral

Topics: financial-reporting, 8-k, operations

Related Tickers: DXCM

TL;DR

Dexcom dropped its 8-K on Feb 13, 2025. Financials and exhibits are in.

AI Summary

On February 13, 2025, Dexcom, Inc. filed an 8-K report detailing its financial results and operations. The filing includes financial statements and exhibits, providing an update on the company's performance for the period ending on the same date. Dexcom, Inc. is incorporated in Delaware and headquartered in San Diego, California.

Why It Matters

This filing provides investors with crucial, up-to-date financial information and operational details for Dexcom, Inc., enabling informed investment decisions.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not indicate any unusual risks or events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by Dexcom, Inc.?

The primary purpose of this 8-K filing is to report on Dexcom, Inc.'s Results of Operations and Financial Condition, and to provide Financial Statements and Exhibits.

On what date was this 8-K report filed?

This 8-K report was filed on February 13, 2025.

Where is Dexcom, Inc.'s principal executive office located?

Dexcom, Inc.'s principal executive office is located at 6340 Sequence Drive, San Diego, CA 92121.

In which state is Dexcom, Inc. incorporated?

Dexcom, Inc. is incorporated in Delaware.

What is the SIC code for Dexcom, Inc.?

The Standard Industrial Classification (SIC) code for Dexcom, Inc. is 3841, which corresponds to Surgical & Medical Instruments & Apparatus.

From the Filing

0001093557-25-000029.txt : 20250213 0001093557-25-000029.hdr.sgml : 20250213 20250213160333 ACCESSION NUMBER: 0001093557-25-000029 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250213 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250213 DATE AS OF CHANGE: 20250213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DEXCOM INC CENTRAL INDEX KEY: 0001093557 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 330857544 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51222 FILM NUMBER: 25620063 BUSINESS ADDRESS: STREET 1: 6340 SEQUENCE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8582000200 MAIL ADDRESS: STREET 1: 6340 SEQUENCE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 dxcm-20250213.htm 8-K dxcm-20250213 false 0001093557 0001093557 2025-02-13 2025-02-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 13, 2025 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 6340 Sequence Drive , San Diego , CA 92121 (Address of Principal Executive Offices) ( Zip Code) ( 858 ) 200-0200 (Registrant’s Telephone Number, Including Area Code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, $0.001 Par Value Per Share DXCM Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐ ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On February 13, 2025, DexCom, Inc. (“Dexcom”) issued a press release announcing its financial results for the quarter and year ended December 31, 2024 and certain other information. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02, including Exhibit 99.1 hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of Dexcom under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and regardless of any gene

View on Read The Filing